




Searching News Database: CLL
HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
HSMN NewsFeed - 18 Sep 2014
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
HSMN NewsFeed - 28 Nov 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 23 Jul 2008
Vaccine Executive Staph Bakali Joins Genocea Biosciences' Board of Directors
Vaccine Executive Staph Bakali Joins Genocea Biosciences' Board of Directors
HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
HSMN NewsFeed - 25 Jan 2008
Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 5 Mar 2007
Stem Cell Innovations Names Ian Lyons, Ph.D., U.S. Chief Scientific Officer
Stem Cell Innovations Names Ian Lyons, Ph.D., U.S. Chief Scientific Officer
HSMN NewsFeed - 15 Feb 2007
Solos Endoscopy, Inc. Signs Contract to Manufacture and Distribute Innovative Medical Documentation Device
Solos Endoscopy, Inc. Signs Contract to Manufacture and Distribute Innovative Medical Documentation Device
HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
HSMN NewsFeed - 9 Jan 2007
Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
HSMN NewsFeed - 16 May 2006
Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Additional items found! 122

Members Archive contains
122 additional stories matching:
CLL
(Password required)
CLL
(Password required)